Trial Profile
Phase Ib double-blind, placebo-controlled, randomised trial investigating the safety and pharmacokinetics of epalrestat [NM-IA-001] in patients with diabetic polyneuropathy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2013
Price :
$35
*
At a glance
- Drugs Epalrestat (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Pharmacokinetics
- 23 Jul 2013 Status changed from not yet recruiting to recruiting as reported in the company media release.
- 04 Jun 2013 New trial record